SYDNEY - Accelerated procedure for the new Australian Covid-19 vaccine called S-Spike. Following the start, in Brisbane, of human trials, the pharmaceutical company CSL (Commonwealth Serum Laboratories) is preparing to produce hundreds of millions of doses, counting, according to the newspaper The Australian today, on the success of the trials and on the approval of Australian and international regulatory bodies.
Scientists from the University of Queensland, led by Trent Munro of the Australian Institute of Bioengineering and Nanotechnology, have predicted that the vaccine has been available for emergency use since January. And the CSL will produce "several million" doses of the antigen before human trials are completed, in the belief that it will be approved through the three stages of the process up to certification.
S-Spike is based on a technology called 'molecular clamp', or 'molecular clamp' to neutralize the infectious properties of the virus and has the advantage of being able to act as a platform that in the future can be recalibrated to face future pandemics. Being based on proteins, it is considered safer to test on people, than formulations that use live virus. Only a few of the approximately 180 developing vaccines in the world are undergoing human testing, which puts S-Spike among the most promising alongside US, British and Chinese candidates.
